

FAMU

COLLEGE OF
**PHARMACY
PHARMACEUTICAL
SCIENCES** INSTITUTE OF PUBLIC HEALTH

FLORIDA **A&M** UNIVERSITY
AND BRISTOL MYERS SQUIBB

PHARMACEUTICAL INDUSTRY
RESIDENCY PROGRAM
2020 - 2021

TABLE OF CONTENTS

Dear Prospective Residents	3
About Florida A&M University.	3
About Bristol Myers Squibb.	4
Steering Committee Leadership	4
First-Year Clinical Residency.	5
Second-Year Pharmaceutical Industry Residency.	5
Current Residents	6
Recent Alumni Testimonies	6
Past Residents	7
Application Process	8

RESIDENCY SITES AND AREAS OF FOCUS



FLORIDA AGRICULTURAL AND
MECHANICAL UNIVERSITY
10650 State Road 84
Davie, FL 33324



BRISTOL MYERS SQUIBB
3401 Princeton Pike
Lawrenceville, NJ 08648

RESIDENCY PROGRAM OVERVIEW



JOHNNIE L. EARLY, II, PH.D, RPh,

Fellow NPhA

**Dean & Professor,
College of Pharmacy
and Pharmaceutical Sciences,
Institute of Public Health,
Florida A&M University**

This pharmaceutical industry residency program was founded in 2009 as a partnership between Florida A&M University and Bristol Myers Squibb. The vision of the residency is to attract and develop a diverse group of talented pharmacists who bring clinical expertise, innovative ideas, and dedication to improving patient outcomes.

The program provides a two-year residency in the therapeutic area of oncology. This residency will provide the residents with a unique experience that bridges the gap between clinical practice and the pharmaceutical industry.

"I am elated that Florida A&M College of Pharmacy and Pharmaceutical Sciences, Institute of Public Health (FAMU CoPPS, IPH) has maintained a fruitful partnership with Bristol Myers Squibb (BMS), a global pharma residency training program, which significantly enhances the skills of practitioners, while improving patients' health and attracting residents who help train PharmD students. The goal of the program is to provide the resident with a substantial experience in the pharmaceutical industry and to emphasize the importance of clinical practice, teaching, and research.

The partnership with BMS aligns with the vision of the College of Pharmacy and Pharmaceutical Sciences to provide excellent pharmaceutical education, research and service activities statewide, nationally, and globally in a dynamic health care environment.

It is my hope that learners consider this unique training program in clinical and pharmaceutical industry."

FLORIDA A&M UNIVERSITY

The Florida A&M College of Pharmacy and Pharmaceutical Sciences, Institute of Public Health program offers PharmD, M.S., and Ph.D. degrees to its students. With its main campus in Tallahassee, Florida, it is the only pharmacy program in the United States that has a fully accredited Institute of Public Health both on-site and managed by the College of Pharmacy. The College has additional practice centers in Jacksonville, Davie, Tampa, and Crestview, which support the infrastructure for the College's statewide commitment to pharmacy education and public service.

The evolution of the College has witnessed the initiation of pharmacy education with just one student in the beginning to now being one of the largest colleges of pharmacy in the country. Currently, the College has more than 1,000 students and faculty. FAMU CoPPS, IPH has a rich history of producing high-caliber graduates capable of providing exceptional pharmaceutical care. Our unique program focuses on academic excellence, research superiority, and community service; this allows us to prepare students for leading roles in the practice of pharmacy, research, and public health.

The Florida A&M College of Pharmacy and Pharmaceutical Sciences, Institute of Public Health reinforces its primary mission through an active role and responsibility in the delivery, outcome, and study of pharmaceutical care services it shares with other healthcare providers. The College is committed to the advancement of pharmaceutical knowledge through teaching, research, and service in a supportive and caring environment that enhances the attainment of educational excellence and the highest standards in professional and ethical practice.

Bristol Myers Squibb is a global BioPharma company firmly focused on its mission to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases. We concentrate our research efforts in four core therapeutic areas: Cardiovascular, Immunoscience, Oncology, and Fibrosis.

At Bristol Myers Squibb, our BioPharma strategy uniquely combines the reach and resources of a major pharmaceutical company with the entrepreneurial spirit and agility of a successful biotechnology company.

Innovation is at the heart of everything we do. Innovation sparks the groundbreaking science of our laboratories, the state-of-the-art processes in our manufacturing plants, and our pioneering approach to product commercialization.

We are committed to the highest standards of ethics and integrity and promoting economic, social, and environmental sustainability. At Bristol Myers Squibb, we are passionate about science, passionate about innovation, and passionate about making a difference in the lives of patients.



STEERING COMMITTEE LEADERSHIP



Left to right: Steering Committee Members: Carol Davis-Shiloh, Mark Peters, Priya Darouian, Thomas Lehman (not pictured)
Executive Sponsors: Samantha Gothelf, Melissa Harris;

"Bristol Myers Squibb is a company committed to patients and offers tremendous opportunities for pharmacists with an interest in joining the pharmaceutical industry. Both of us entered Bristol Myers Squibb through the Rutgers University PharmD Fellowship program, thus have first hand experience on the impact that preceptors, mentors, and the pharmacist community have on our incoming fellows and residents. Now as managers and sponsors of the program, we are proud to foster an environment where members of our PharmD program are provided opportunities to gain experience and new skills that will prepare them for future opportunities to succeed in the pharmaceutical industry."

As leaders at Bristol Myers Squibb, we know the importance of investing in and engaging talent to fulfill our company's mission for patients. The Florida A&M University PharmD Residency is an important part of our talent strategy and key to cultivating the Bristol Myers Squibb culture and its future."

Samantha Gothelf, PharmD and Melissa Harris, PharmD

FIRST-YEAR CLINICAL RESIDENCY



NATHAN E
ERAIKHUEMEN,
PHARM D

**First-Year Residency Director
Assistant Professor of Medicine
& Pharmacy Practice**
Florida A&M University

In the first year, residents will participate in clinical pharmacology and pharmacy practice with emphasis in hematology, oncology, and transplant medicine at practice sites located in South Florida and Florida A&M College of Pharmacy and Pharmaceutical Sciences, Institute of Public Health. The resident will actively provide pharmaceutical care to oncology patients in a variety of areas which include: internal medicine, primary care, ambulatory care, critical care, managed care, transplant, nutrition support, infectious disease, and geriatrics. While at the College, the residents will also participate in workshops, meetings, and other faculty related engagements to promote professional growth.

The resident will also be given the opportunity to participate in the pharmacy and therapeutics committee, perform medication utilization evaluations, and provide continuing education to healthcare practitioners. As an academic requirement, the resident will participate in teaching and preceptorship activities with FAMU student pharmacists enrolled in the college. Residents have the opportunity to:

- Provide pharmaceutical care and patient education within inpatient and outpatient settings
- Deliver lectures to student pharmacists, pharmacists, nurses, and medical residents
- Collaborate with preceptors to educate pharmacy students
- Conduct research with the opportunity to present findings at various conferences
- Interact with healthcare providers to optimize treatment regimens

SECOND-YEAR PHARMACEUTICAL INDUSTRY RESIDENCY

In the second year, the PharmD residents will transition to central New Jersey where they will gain a diverse set of leadership skills and unique cross-functional experiences to launch a successful career in the pharmaceutical industry. Each resident will be positioned on a highly functioning team within the Medical Affairs organization where they can provide significant contributions to the development, launch, and lifecycle management of various assets within our portfolio. Our residents will lead critical initiatives and collaborate with a variety of US and world-wide BMS colleagues, key medical opinion leaders, health care professionals, and many others. The residents will also be involved in providing their clinical expertise, from their first-year experience, to develop effective strategies to better meet the needs of our customers and improve patient care.

The PharmD residents will gain the following skills and knowledge in these key areas:

- Understand the roles and responsibilities of a PharmD in the Medical Affairs organization
- Engage with cross-functional teams including field medical, home office medical, world-wide publications & scientific content, and commercial stakeholders
- Collaborate with authors/agencies to develop medical publications to inform clinical practice
- Lead the development and execution of comprehensive publication plans (e.g. abstracts, congress posters, oral presentations, manuscripts, review articles) to ensure BMS scientific data is communicated effectively to health care professionals around the world
- Engage closely with field medical colleagues to provide trainings and translate insights from the field to guide strategy

CURRENT RESIDENTS



AARON NORTH
PHARM D
**US Immunoscience
Medical Strategy -
Ozanimod Resident**
Lawrenceville, NJ
(2nd Year)



RICHIE ONWUCHEKWA
PHARM D
**WW Oncology
Publications - Early
Transition Assets Resident**
Lawrenceville, NJ
(2nd Year)



FRANCO DICKSON
PHARM D
Oncology Clinical Resident
Davie, FL
(1st Year)



RAENA RHONE
PHARM D
Oncology Clinical Resident
Davie, FL
(1st Year)



RECENT ALUMNI TESTIMONIES



IMANI PELT, PHARM D
WW Oncology Publications - Early Transition Asset, Bristol Myers Squibb
WW Immuno-Oncology Publication & Scientific Content Resident, 2019-2020



"My time as a Florida A&M University/Bristol Myers Squibb resident was truly a unique and rewarding experience. During my time as a resident, I was afforded the opportunity to develop my clinical skills, evolve as an effective communicator, and keep a patient focused outlook allowing for clear direction to truly execute a company's mission. Being an integral part of the medical team in the clinical setting and by working as an adjunct professor really challenged my clinical capabilities resulting in a deeper understanding of oncology and hematology. The skills obtained during my first year allowed me to successfully transition to the publication team during my second year, where I was able to help drive the development of publications to major medical and scientific journals. In all, this was a fulfilling experience, and I would not have been successful if it weren't for the great leadership and mentorship received from the leadership team and preceptors along the way. This program is truly one of a kind, and I am so honored to say I was able to have this experience."



DONALLE JOHNSON, PHARM D
Oncology Medical Science Liaison, Eisai Inc.
US Immuno-Oncology Medical Strategy Resident, 2019-2020



"I am extremely grateful to be an alumnus of the Florida A&M University/Bristol Myers Squibb PharmD Residency Program. This unique program enabled me to grow professionally and develop transferable skills to launch my career as a pharmaceutical industry professional. In collaborating with healthcare providers and academic scholars, this program provided me an opportunity to translate ideals from bedside-to-bench. My clinical experience equipped me with foundational skills to excel within the Medical Affairs organization at Bristol Myers Squibb. At BMS I was able to gain a more granular understanding of clinical research, and how industry professionals corroborate with key external influencers to develop strategy, cemented in improving patients' lives. This exposure coupled with traveling abroad and disclosing data as a principal investigator at the World Conference on Lung Cancer, granted me an opportunity of a lifetime. The hallmark of my journey is embedded in the mentorship and guidance from preceptors and alumni. I am forever indebted to the FAMU/BMS Residency Program."



BRYANDT DOUGLAS
PHARM D
Hematology Medical Science Liaison, Bristol Myers Squibb
Worldwide Oncology Medical Publications Resident, **2017-2019**



VICTORIA SPENCE,
PHARM D
Thoracic & Immuno-Oncology Medical Science Liaison, AstraZeneca
US Immuno-Oncology Medical Strategy Resident, **2017-2019**



KEVIN CLARKE,
PHARM D
Global Medical Communication Manager, Vertex Pharmaceuticals
Worldwide Oncology Medical Publications Resident, **2016-2018**



JESSIE HWANG,
PHARM D
Associate Director, Business Development, Bristol Myers Squibb
Worldwide Oncology Medical Publications Resident, **2017-2018**



MARISSA WEST,
PHARM D
I-O Medical Scientist, US Medical Oncology, Bristol Myers Squibb
Worldwide Oncology Medical Publications Resident, **2015-2017**



SHANADA MONESTIME,
PHARM D, BCOP
Hematology/Oncology Assistant Professor, Univ. of North Texas College of Pharmacy
Worldwide Oncology Medical Content/Information Resident, **2015-2017**



JADE HOANG,
PHARM D
Rheumatology Professional Marketing, Bristol Myers Squibb
R&D Strategy and Analytics Resident, **2014-2015**



TEMEITOPE OSIYEML,
PHARM D
Medical Science Director, Genentech
Medical Information Resident, **2014-2015**



IJEOMA NWOSU,
PHARM D
I-O Medical Scientist, US Medical Oncology, Bristol Myers Squibb
Medical Information Resident, **2013-2014**



KARINA UTKINA,
PHARM D
Medical Director, Medical Affairs Pharmacosmos Therapeutics Inc.
R&D Strategy and Analytics Resident, **2013-2014**



DAWN BEY,
PHARM D, MBA
Director, Field Real World Evidence, Taiho Oncology
R&D Strategy and Analytics Resident, **2012-2013**



OLAKIITAN BABALOLA,
PHARM D
Oncology Regional Medical Scientific Director, Merck
Medical Information Resident, **2012-2013**



LINA SINGLETON,
PHARM D
Director Strategy & Operations U.S. Oncology Medical, Novartis
Medical Information Resident, **2009-2010**



CHRISTINA WRIGHT,
PHARM D
Immunology/Multiple Sclerosis Senior Regional Medical Science Liaison, Bristol Myers Squibb
Medical Information Resident, **2011-2012**





Bristol Myers Squibb

APPLICATION PROCESS

APPLICATION MATERIALS DUE MONDAY, NOVEMBER 2ND 2020

QUALIFICATIONS:

- **Required:** Doctor of Pharmacy (PharmD) degree from an accredited institution prior to the start of the residency.
- Selected candidates must be licensed as a pharmacist prior to or within 90 days of starting the 1st Year Clinical Residency.
- This program does not currently sponsor candidates for H-1B status to work as pharmacy residents.

SUBMISSION:

- Click [here](#) to submit application material
- For questions please contact FAMU@bms.com

APPLICATION MATERIALS:

- Letter of Intent
- Curriculum vitae
- Unofficial Transcript
- Three letters of recommendation

PROCESS:

- Selected candidates will be contacted for an onsite interview
- One candidate will be selected for each position
- All candidates will be notified of their status by the end of February 2021